- Home
- RPTX
as 11-21-2024 4:00pm EST
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
| Founded: | 2016 | Country: | Canada |
| Employees: | N/A | City: | SAINT-LAURENT |
| Market Cap: | 152.4M | IPO Year: | 2020 |
| Target Price: | $10.00 | AVG Volume (30 days): | 113.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.71 - $8.49 | Next Earning Date: | 11-07-2024 |
| Revenue: | $66,524,000 | Revenue Growth: | 18.19% |
| Revenue Growth (this year): | 13.36% | Revenue Growth (next year): | -89.67% |
Latest Repare Therapeutics Inc. News
RPTX Breaking Stock News: Dive into RPTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
Industry Analysts Just Made A Notable Upgrade To Their Repare Therapeutics Inc. (NASDAQ:RPTX) Revenue Forecasts
Business Wire
10 days ago
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Business Wire
15 days ago
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
Clinical Trials Arena
a month ago
Repare Therapeutics’ individualised anaemia management trial shows promise
Business Wire
a month ago
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Zacks
a month ago
RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug
Clinical Trials Arena
a month ago
Repare Therapeutics doses first subject in Phase I solid tumour trial
Business Wire
a month ago
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
Compare RPTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RPTX Repare Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.